Adial Pharmaceuticals, Inc. (ADIL)
NASDAQ: ADIL · Real-Time Price · USD
0.5140
+0.0338 (7.04%)
At close: Jul 25, 2025, 4:00 PM
0.5400
+0.0260 (5.06%)
After-hours: Jul 25, 2025, 7:59 PM EDT

Company Description

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders.

The company’s lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder.

It is also involved in the development of drug candidates for non-opioid pain reduction and other diseases and disorders.

Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Glen Allen, Virginia.

Adial Pharmaceuticals, Inc.
Adial Pharmaceuticals logo
CountryUnited States
Founded2010
IPO DateJul 30, 2018
IndustryBiotechnology
SectorHealthcare
Employees5
CEOCary Claiborne

Contact Details

Address:
4870 Sadler Road, Suite 300
Glen Allen, Virginia 23060
United States
Phone(804) 487-8196
Websiteadial.com

Stock Details

Ticker SymbolADIL
ExchangeNASDAQ
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
CIK Code0001513525
CUSIP Number00688A106
ISIN NumberUS00688A2050
Employer ID80-0667150
SIC Code2834

Key Executives

NamePosition
Cary John Claiborne MBAChief Executive Officer, President and Director
Tony GoodmanChief Operating Officer and Director
Vinay Shah A.C.A., M.B.A.Chief Financial Officer and Treasurer
John R. Martin J.D.Chief Legal Officer
Andrew TaubmanVice President of Corporate Development
Dr. Brigitte Robertson M.D.Acting Chief Medical Officer
Abel Svitavsky CPAController

Latest SEC Filings

DateTypeTitle
Jul 16, 20258-KCurrent Report
Jul 10, 20258-KCurrent Report
Jun 27, 2025DEFR14AFiling
Jun 23, 2025SCHEDULE 13GFiling
Jun 18, 20258-KCurrent Report
Jun 18, 2025424B5Filing
Jun 17, 2025PRER14AFiling
Jun 16, 2025EFFECTNotice of Effectiveness
Jun 16, 20258-KCurrent Report
Jun 13, 2025S-1/A[Amend] General form for registration of securities under the Securities Act of 1933